VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Neal Shore on Treatment of Elderly Patients With mCRPC

Neal Shore, MD
Published: Wednesday, Sep 14, 2016


Neal Shore, MD, the medical director of Carolina Urologic Research Center, discusses the role for abiraterone in patients with chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
 
The elderly population can be immunocompromised, worsening fatigue, more deconditioning, and they are often already on androgen deprivation therapy (ADT), says Shore.
 
When selecting therapy, it is important not to exasperate issues that may already exist in elderly patients like fatigue, lack of appetite, or their diminished participation in extracurricular type activities, specifically their physician activity. Some elderly patients may also have challenges in cognitive function. Abiraterone is very safe and well-tolerated in that patient population of elderly patients, says Shore.

Neal Shore, MD, the medical director of Carolina Urologic Research Center, discusses the role for abiraterone in patients with chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
 
The elderly population can be immunocompromised, worsening fatigue, more deconditioning, and they are often already on androgen deprivation therapy (ADT), says Shore.
 
When selecting therapy, it is important not to exasperate issues that may already exist in elderly patients like fatigue, lack of appetite, or their diminished participation in extracurricular type activities, specifically their physician activity. Some elderly patients may also have challenges in cognitive function. Abiraterone is very safe and well-tolerated in that patient population of elderly patients, says Shore.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x